Gene Logic explores drug-repositioning options

By Elaine Rigoli

Tampa, Fla., Sept. 22 - Gene Logic, Inc. said a business review has confirmed the potential for its drug-repositioning business to enhance long-term shareholder value.

Market research conducted by a strategy-consulting firm validated large pharmaceutical companies' interest in the emerging field of drug repositioning as an important option for obtaining new, late-stage research and development pipeline drug candidates, according to a news release.

The Gaithersburg, Md., drug services company said it believes its approach to repositioning high-quality drug candidates that stalled in clinical development for reasons other than toxicity could, in many cases, enable these candidates to return directly into phase 2 clinical development.

For example, the business review confirmed that the company's prior strategy for its Genomics business, intended to compensate for the impact of changing market conditions, will not reverse recent sales trends.

The company said the Genomics assets are a key part of the technology platform used in the company's drug-repositioning business to find new therapeutic uses for partners' drug candidates, and they will continue to be leveraged in these efforts.

The company suggested that the assets and technologies of its Genomics business may have additional value in areas such as clinical biomarker development and molecular diagnostics.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.